Drug Type Small molecule drug |
Synonyms MK 1496 |
Target |
Action inhibitors |
Mechanism PLK1 inhibitors(Polo like kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H24N2O |
InChIKeyKUHBBYPXWKYKKR-GXFFZTMASA-N |
CAS Registry1037254-47-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Apr 2009 | |
| Solid tumor | Phase 1 | Japan | - |
Phase 1 | 27 | (MK-1496 20 mg (21-Day Cycle)) | mvgressqix = gbyavkhwly fiqguxzlog (kvvnnydlwv, fgxmqrgiiz - wsgdrlsoan) View more | - | 26 Oct 2012 | ||
(MK-1496 40 mg (21-Day Cycle)) | mvgressqix = tklgmavffj fiqguxzlog (kvvnnydlwv, gfxxnvqmch - yhbtojcdoq) View more | ||||||
Phase 1 | 17 | bgglpuncik(dzewaxkjum) = umgblrsair gdsbwwudfp (bhkohhjzdd ) | - | 20 May 2011 |





